Jennifer So, MD
Critical Care Medicine · Baltimore, MDNPI 1700149440
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,835 of the $2,721 with a category attached, or 67.4%. 8 manufacturers reported payments, led by Inspire Medical Systems, Inc. at 59.1% of the total. Reporting peaked in 2023 at $1,441 and has fallen 69.3% since, to $442 in 2025.
Across 24 payments — averaging $113.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Inspire Medical Systems, Inc.$2K
- Fisher & Paykel Healthcare Inc$254
- Avadel CNS Pharmaceuticals, LLC$250
- ZOLL Respicardia, Inc.$141
- Itamar Medical Inc$131
- Jazz Pharmaceuticals Inc.$119
- plus $217 from 2 others
What the payments were for
- Travel & lodging$78629%
- Food & beverage$1,83567%
- Education$1004%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Inspire Medical Systems, Inc. | 16 | $1,609 |
| Fisher & Paykel Healthcare Inc | 1 | $254 |
| Avadel CNS Pharmaceuticals, LLC | 2 | $250 |
| ZOLL Respicardia, Inc. | 1 | $141 |
| Itamar Medical Inc | 1 | $131 |
| Jazz Pharmaceuticals Inc. | 1 | $119 |
| Optinose US, Inc. | 1 | $117 |
| Genentech USA, Inc. | 1 | $100 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FISHER & PAYKEL HEALTHCARE$1,272
- Inspire$1,216
- LUMRYZ$250
- remede System$141
- WatchPATONE$131
- XYWAV$119
- Xhance$117
How this compares
$2,721 in reported general payments places this provider in the 85th percentile of 231 critical care medicine providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 62 | $51,299 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 55 | $35,833 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 69 | $2,540 |
| Ventolin HfaAlbuterol Sulfate | 17 | $918 |
Paid to pharmacies, not to this prescriber.
Other critical care medicine in Baltimore
- David Feller KopmanBaltimore$236K
- Elizabeth HuntBaltimore$182K
- Edward BrittBaltimore$70K
- Nirav ShahBaltimore$55K
- Steven KellerBaltimore$31K
- Nader HabashiBaltimore$25K
- van HoldenBaltimore$21K
- Renee DixonBaltimore$10K
- Wendy ZiaiBaltimore$8K
- Andrea LevineBaltimore$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.